Ishita Drugs & Industries Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "76.01",
    "chg": -0.05,
    "chgp": "-0.07%",
    "dir": -1,
    "prev_price": "76.06",
    "mcapval": "23.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE806D01016",
    "curr_date": "Apr 20",
    "curr_time": "",
    "bse_nse_vol": "107 ",
    "exc_status": "Active",
    "traded_date": "Apr 20, 2026",
    "traded_date_str": "2026 04 20",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Technical Weakness and Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amid-technical-weakness-and-flat-financials-3945189",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IshitaDrugsIndu_mojoScore_3945189.png",
        "date": "2026-04-14 08:17:57",
        "description": "Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 Apr 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. Despite some long-term outperformance relative to the Sensex, the company’s micro-cap status, flat recent financial results, and bearish technical signals have prompted a reassessment of its investment appeal."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements and Valuation Shift",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-upgraded-to-sell-on-technical-improvements-and-valuation-shift-3936553",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/IshitaDrugsIndu_mojoScore_3936553.png",
        "date": "2026-04-08 08:08:15",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite persistent challenges in financial trends and quality parameters. The pharmaceutical micro-cap’s recent price surge of over 10% in a single day underscores renewed investor interest, yet fundamental concerns remain."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shifts Signal Price Attractiveness Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shifts-signal-price-attractiveness-amid-market-volatility-3923273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/IshitaDrugsIndu_valuationdot_3923273.png",
        "date": "2026-03-30 08:00:53",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade. Despite a recent sharp decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd: Valuation Shift Signals Changing Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-ltd-valuation-shift-signals-changing-price-attractiveness-3884246",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/IshitaDrugsIndu_valuationdot_3884246.png",
        "date": "2026-03-11 08:00:31",
        "description": "Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid mixed financial metrics and sector dynamics. Despite a robust share price rally in recent weeks, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers warrant a cautious approach from investors."
      },
      {
        "title": "Are Ishita Drugs & Industries Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-industries-ltd-latest-results-good-or-bad-3826846",
        "imagepath": "",
        "date": "2026-02-07 19:19:19",
        "description": "Ishita Drugs & Industries Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.14 crores, which reflects a substantial decline compared to the previous quarter's ₹0.30 crores, indicating ongoing volatility in earnings. Revenue also saw a notable contraction, falling to ₹3.07 crores from ₹5.40 crores in Q1 FY26, marking a sharp decrease of 43.15% quarter-on-quarter. This decline in revenue is concerning as it highlights the company's struggle to maintain consistent sales growth, with year-on-year revenue also down by 6.12%.\n\nThe operating margin for the quarter was recorded at 6.19%, which is a slight decrease from the previous quarter's 6.48%. This suggests that while the company has managed to maintain some cost discipline, the overall profitability has been adversely affected by the significant drop in sales volume. Additionally, the..."
      },
      {
        "title": "Ishita Drugs Q2 FY26: Profit Slumps 26% as Revenue Volatility Persists",
        "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q2-fy26-profit-slumps-26-as-revenue-volatility-persists-3826780",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/IshitaDrugsIndu_quaterlyResult_3826780.png",
        "date": "2026-02-07 17:46:41",
        "description": "Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹21.00 crores, reported disappointing results for Q2 FY26, with net profit declining 26.32% quarter-on-quarter to ₹0.14 crores from ₹0.30 crores in Q1 FY26. The sharp contraction in profitability came despite the company maintaining a relatively stable operating margin profile, raising concerns about the sustainability of earnings amidst persistent revenue volatility."
      }
    ],
    "total": 111,
    "sid": "444125",
    "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Non Applicability Of Regulation 32(1) Of SEBI(LODR) Regulations 2015",
      "datetime": "13-Apr-2026",
      "details": "Non - applicability of Regulation 32(1) of SEBI(LODR) Regulations 2015 for the year ended 31st March 2026.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "10-Apr-2026",
      "details": "Complaince Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31st March 2026 as attached.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2026",
      "details": "The trading window for dealing in securities of the Company by designated persons stands closed from Wednesday 01st April 2026 till 48 hours after the declaration of the Audited Financial Results for the quarter and Financial year ended 31st March 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Technical Weakness and Flat Financials

2026-04-14 08:17:57

Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 Apr 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. Despite some long-term outperformance relative to the Sensex, the company’s micro-cap status, flat recent financial results, and bearish technical signals have prompted a reassessment of its investment appeal.

Read full news article

Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements and Valuation Shift

2026-04-08 08:08:15

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite persistent challenges in financial trends and quality parameters. The pharmaceutical micro-cap’s recent price surge of over 10% in a single day underscores renewed investor interest, yet fundamental concerns remain.

Read full news article

Ishita Drugs & Industries Ltd: Valuation Shifts Signal Price Attractiveness Amid Market Volatility

2026-03-30 08:00:53

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade. Despite a recent sharp decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Read full news article

Ishita Drugs & Industries Ltd: Valuation Shift Signals Changing Price Attractiveness

2026-03-11 08:00:31

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid mixed financial metrics and sector dynamics. Despite a robust share price rally in recent weeks, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers warrant a cautious approach from investors.

Read full news article

Are Ishita Drugs & Industries Ltd latest results good or bad?

2026-02-07 19:19:19

Ishita Drugs & Industries Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.14 crores, which reflects a substantial decline compared to the previous quarter's ₹0.30 crores, indicating ongoing volatility in earnings. Revenue also saw a notable contraction, falling to ₹3.07 crores from ₹5.40 crores in Q1 FY26, marking a sharp decrease of 43.15% quarter-on-quarter. This decline in revenue is concerning as it highlights the company's struggle to maintain consistent sales growth, with year-on-year revenue also down by 6.12%. The operating margin for the quarter was recorded at 6.19%, which is a slight decrease from the previous quarter's 6.48%. This suggests that while the company has managed to maintain some cost discipline, the overall profitability has been adversely affected by the significant drop in sales volume. Additionally, the...

Read full news article

Ishita Drugs Q2 FY26: Profit Slumps 26% as Revenue Volatility Persists

2026-02-07 17:46:41

Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹21.00 crores, reported disappointing results for Q2 FY26, with net profit declining 26.32% quarter-on-quarter to ₹0.14 crores from ₹0.30 crores in Q1 FY26. The sharp contraction in profitability came despite the company maintaining a relatively stable operating margin profile, raising concerns about the sustainability of earnings amidst persistent revenue volatility.

Read full news article

View All News